Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 6/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CPB1 | P15086 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP7 | P09237 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | MMP14 | P50281 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29549748 | 0.91 | TGM2 (0.42) | PTPN1TGM2HTR2ACTSLP2RX7 | |
| SCHEMBL30471718 | 0.78 | SSTR3 (0.50) | PTPN1TGM2HTR2ACTSLCTSB | |
| SCHEMBL3726655 | 0.76 | TGM2 (0.46) | TGM2CTSLP2RX7CTSBMMP1 | |
| SCHEMBL29522093 | 0.76 | PTPN1 (0.40) | PTPN1TGM2CTSLP2RX7 | |
| SCHEMBL28538964 | 0.73 | HTR2A (0.49) | TGM2HTR2ADPP8DPP9 | |
| SCHEMBL15669247 | 0.72 | HTR2A (0.35) | PTPN1TGM2HTR2ADPP8DPP9 | |
| SCHEMBL15669378 | 0.71 | HTR2A (0.40) | PTPN1TGM2HTR2AMMP1MMP2 | |
| SCHEMBL17161225 | 0.71 | HTR2A (0.44) | TGM2HTR2ADPP8DPP9 | |
| SCHEMBL2028970 | 0.68 | TGM2 (0.62) | TGM2DPP8DPP9MMP2MMP9 | |
| SCHEMBL34467666 | 0.68 | TGM2 (0.61) | TGM2DPP8DPP9MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098621-A1 | ENGINEERED ANTIBODY WITH SITE-SPECIFIC CONJUGATION, ANTIBODY-DRUG CONJUGATE, AND APPLICATION THEREOF | 百力司康生物医药(杭州)有限公司 | 2026-05-15 | — | — | WO | claimed |
| US-12605457-B2 | Modified EGFR antibody with reduced affinity, drug conjugate, and use thereof | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2026-04-21 | — | — | US | claimed |
| US-20240342304-A1 | Tetravalent Antibody-Drug Conjugates and Use Thereof | BLISS BIOPHARMACEUTICAL HANGZHOU CO LTD (CN) | 2024-10-17 | — | — | US | claimed |
| US-11951173-B2 | Tetravalent antibody-drug conjugates and use thereof | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2024-04-09 | — | — | US | claimed |
| US-20240075154-A1 | ENGINEERED ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | BLISS BIOPHARMACEUTICAL HANGZHOU CO LTD (CN) | 2024-03-07 | — | — | US | claimed |
| US-20240009318-A1 | MODIFIED EGFR ANTIBODY WITH REDUCED AFFINITY, DRUG CONJUGATE, AND USE THEREOF | BLISS BIOPHARMACEUTICAL HANGZHOU CO LTD (CN) | 2024-01-11 | — | — | US | claimed |
| US-20240002527-A1 | ANTI-CD73 ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | BLISS BIOPHARMACEUTICAL HANGZHOU CO LTD (CN) | 2024-01-04 | — | — | US | claimed |
| US-20230414781-A1 | ANTI-CD276 ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | BLISS BIOPHARMACEUTICAL HANGZHOU CO LTD (CN) | 2023-12-28 | — | — | US | claimed |
| EP-4247855-A1 | ANTI-CD73 ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2023-09-27 | — | — | EP | claimed |
| EP-4247854-A1 | ANTI-CD276 ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2023-09-27 | — | — | EP | claimed |
| EP-4247853-A1 | MODIFIED EGFR ANTIBODY WITH REDUCED AFFINITY, DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2023-09-27 | — | — | EP | claimed |
| EP-4247425-A1 | ENGINEERED ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2023-09-27 | — | — | EP | claimed |
| CN-116528911-A | anti-CD 73 antibody, antibody-conjugated drug and application thereof | 百力司康生物医药(杭州)有限公司 | 2023-08-01 | — | — | CN | claimed |
| CN-116419929-A | Engineered EGFR antibodies with reduced affinity, drug conjugates and uses thereof | 百力司康生物医药(杭州)有限公司 | 2023-07-11 | — | — | CN | claimed |
| CN-116406382-A | anti-CD 276 antibody, antibody-conjugated drug and application thereof | 百力司康生物医药(杭州)有限公司 | 2023-07-07 | — | — | CN | claimed |
| WO-2022104692-A1 | ENGINEERED ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2022-05-27 | — | — | WO | claimed |
| WO-2022105878-A1 | MODIFIED EGFR ANTIBODY WITH REDUCED AFFINITY, DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2022-05-27 | — | — | WO | claimed |
| WO-2022105879-A1 | ANTI-CD276 ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2022-05-27 | — | — | WO | claimed |
| WO-2022105873-A1 | ENGINEERED ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2022-05-27 | — | — | WO | claimed |
| WO-2022105881-A1 | ANTI-CD73 ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2022-05-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605457-B2 | Modified EGFR antibody with reduced affinity, drug conjugate, and use thereof | EGFR, ERBB2, IGSF11 | PTPN1 653/4885TGM2 790/4885HTR2A 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.